Oxford Sciences Innovation Plc (OSI) announces two new Board-level appointments, with experienced technology entrepreneur Charles Conn joining as Chief Executive and former Google CFO Patrick Pichette joining as Chairman.
The University of Oxford and Harrington Discovery Institute at University Hospitals have announced a new affiliation to advance therapies for rare diseases. The joint program combines capabilities to improve treatment options globally for patients with rare diseases.
In a Medium interview, Professor Matthew Wood, a professor of Neuroscience in the Department of Paediatrics, talks about his work and the advances that a new Rare Diseases Centre could herald for the future of rare disease and genetics.
Researchers in Oxford have carried out the world\u2019s first gene therapy operation to tackle the root cause of age-related macular degeneration (AMD), the UK\u2019s most common cause of sight loss.
A new consortium of 27 partners coordinated by the Nuffield Department of Clinical Neurosciences will tackle the challenge of discovery and characterisation of blood-brain barrier targets and transport mechanisms for brain delivery of therapeutics to treat neurodegenerative and metabolic diseases.
Oxford University, through its innovation arm Oxford University Innovation (OUI), has entered into an option agreement for a universal influenza vaccine with US-based startup Blue Water Vaccines (BWV), which is raising $15m to support development of the flu shot.
Ten innovative data solutions to healthcare challenges, including a project led by the Head of the Nuffield Department of Surgical Sciences (NDS), Professor Freddie Hamdy, are set to receive a share of \u00a33 million Government funding following a UK-wide competition. The initiatives will see NHS, universities and companies combining expertise and using health data responsibly to drive innovation and improve health outcomes for people across the UK.
Medical Sciences Business Development & Partnering Team are delighted to announce that the AIMday in Advanced Therapies & Regenerative Medicine is now open for registration by academics.
The National Institute for Health and Care Excellence has approved the use in the NHS of ex-vivo machine perfusion for preservation of livers donated for transplants.
The UK\u2019s first dedicated Vaccines Manufacturing Innovation Centre (VMIC), announced by Business Secretary Greg Clark MP, represents a major commercial opportunity and also a new front line in the nation\u2019s defence against global pandemic threats.
Innovate UK and industry are to invest more than \u00a317.5 million in the University of Oxford to develop artificial intelligence (AI) healthcare applications to benefit patients.
Researchers at the University of Oxford, in a new industry partnership with Axol Bioscience of Cambridge, have secured funding from the BBSRC to collaborate in creating human models of the cerebellum with induced pluripotent stem cells (iPSCs) for studies of neurological disorders.
A smartphone application for women with gestational diabetes, developed with support from NIHR Oxford Biomedical Research Centre, has been launched commercially.
A new test that predicts with almost 100 per cent accuracy that a pregnant woman will not develop pre-eclampsia within the following seven days has been given the green light to be used as standard clinical practice in one of the UK\u2019s biggest acute hospital trusts.
Positive results of the world\u2019s first gene therapy trial for a genetic cause of blindness known as choroideremia have been reported in Nature Medicine.
![\"Circuit](\"https://www.medsci.ox.ac.uk/news/oxford-sciences-innovation-plc-appoints-new-ceo-and-chairman-prepares-for-next-phase-of-growth/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n